Eleven brands across six molecules, made almost entirely by two companies Novo Nordisk and Eli Lilly: Semaglutide (Novo Nordisk) Ozempic, Wegovy, Rybelsus Tirzepatide (Eli Lilly) Mounjaro, Zepbound Liraglutide (Novo Nordisk) Victoza, Saxenda Dulaglutide (Eli Lilly) Trulicity Exenatide (AstraZeneca) Byetta, Bydureon BCise Lixisenatide (Sanofi) Adlyxin, no longer marketed in the US For weight management , the FDA has approved Wegovy, Zepbound and Saxenda
C.SobeyC
Research Protocols & Dosage Evidence-based research protocols, administration routes, and dosage considerations for BPC-157 are detailed in the full compound profile
The higher doses also bring the possibility of temporary side effect recurrence
Peptide degradation is real, measurable, and irreversible